Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 13,749 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Healthy
Interventions: Cefazolin; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumor
Interventions: BG-75098, BGB-43395, Fulvestrant; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more

Conditions: Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions: betaquik®; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: N6022, Normal saline; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more

Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions: XMT-1001; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 12
States / cities: Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 9 more

Conditions: Breast Cancer
Interventions: Sample collection, Patient-reported outcomes; Other · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash; Drug · Other
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more

Conditions: Neovascular Age-related Macular Degeneration, nAMD
Interventions: ABP 938 8 mg, Aflibercept (US) 8 mg; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 55
States / cities: Fullerton, California • Long Beach, California • Modesto, California + 50 more

Conditions: Diabetes Mellitus, Hypoglycemia
Interventions: Patient Group (Hypoglycemia Prevention Program), Primary Care Physician Group, Clinic Staff Group; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BMS-986020, Placebo matching with BMS-986020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more

Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions: Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 482
States / cities: Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more

Conditions: Pain, Pancreatic Cancer
Interventions: morphine sulfate, Medtronic intrathecal pump; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hippocampal Overactivity, Dementia
Interventions: AGB101, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dengue
Interventions: TetraVax-DV-TV003, rDEN2∆30-7169, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Mitral Annular Calcification
Interventions: Mitral Valve Replacement (MVR) with Sapien3; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Wynnewood, Pennsylvania + 3 more

Conditions: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more

Conditions: Chronic Hepatitis C
Interventions: albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Docetaxel, Laboratory Biomarker Analysis, Prednisone, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Rilimogene Galvacirepvec; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 14
States / cities: Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more

Conditions: Bipolar Depression
Interventions: NeuroStar TMS; Device
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Rochester, Minnesota

Conditions: Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations
Interventions: Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autosomal Dominant Polycystic Kidney, ADPKD
Interventions: Bardoxolone methyl oral capsule, Placebo oral capsule; Drug
Lead sponsor: Biogen; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 83
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 69 more

Search by objective public record fields.

Cefazolin PK Study 3g vs 2g

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Study of a Primary Care Hypoglycemia Prevention Program

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

An Open Label Trial of TMS Therapy for Bipolar Depression

Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON